Liquid Biopsy Market Intelligence: Size, Share and Growth Outlook Through 2036

Market Overview

Market Size and Outlook

• The liquid biopsy market was valued at USD 6.4 billion in 2025 and is forecast to reach USD 29.2 billion by 2036 at a 14.8% CAGR.
• Industry revenue is projected to reach USD 7.3 billion by 2026-end before expanding through the 2026-2036 forecast period.
• Circulating Tumor Cells (CTCs) is projected to lead with a 70.0% share, while Blood is expected to lead with a 87.4% share.

Demand and Growth Drivers

• Rising cancer incidence and demand for non-invasive molecular profiling are creating sustained growth in liquid biopsy adoption across diagnostic and treatment monitoring applications.
• Clinical validation of circulating tumor cell and cell-free DNA assays is expanding reimbursement coverage and physician adoption across oncology treatment pathways.
• Growth in companion diagnostic applications, where liquid biopsy guides targeted therapy selection, creates structured demand linked to precision oncology program expansion.
• China leads expansion at 20.0% CAGR, followed by India at 18.5%, where healthcare investment and molecular diagnostics infrastructure are accelerating adoption.

Analyst Perspective

• The liquid biopsy market is transitioning from single-cancer diagnostic applications toward multi-cancer early detection platforms that screen for multiple tumor types from a single blood draw.
• Adoption is increasing due to clinical evidence demonstrating liquid biopsy utility for treatment selection, minimal residual disease monitoring, and recurrence surveillance.
• Technology advancement in next-generation sequencing sensitivity enables detection of tumor-derived biomarkers at earlier disease stages.

Market Dynamics

Drivers, Restraints, and Opportunities

• Rising cancer incidence and demand for non-invasive molecular profiling sustain adoption across diagnostic and treatment monitoring applications.
• Reimbursement complexity and payer coverage variability across geographies constrain adoption in markets where liquid biopsy tests lack established coverage pathways.
• Multi-cancer early detection platforms represent the largest growth opportunity, with potential to create population-scale screening programs that expand the addressable market.
• Liquid biopsy testing is now supported by NCCN and ESMO clinical practice guidelines for certain indications such as EGFR mutation testing in NSCLC.
• Inconsistent payer coverage for novel multi-cancer detection applications without long-term clinical outcome data remains a material adoption barrier.

Clinical Adoption Trends

• Liquid biopsy is increasingly integrated as a companion diagnostic for targeted therapy and immunotherapy selection as approved targeted cancer therapies grow.
• Blood-based tests capable of detecting signals from multiple cancer types simultaneously have potential to dramatically expand liquid biopsy test volumes.
• Medicare coverage decisions in the USA and Health Technology Assessment outcomes in Europe strongly impact commercial uptake rates and time to market penetration.

Segmentation Analysis

Biomarker Type Outlook

• Circulating Tumor Cells (CTCs) account for 70.0% of biomarker type share, reflecting established clinical evidence for CTC enumeration in treatment response monitoring.
• Clinical validation of CTC enumeration for prognosis assessment has been demonstrated in metastatic breast, prostate, and colorectal cancers.
• Advanced CTC analysis platforms offer molecular characterization of captured cells, including mutation profile and drug sensitivity information.

Sample Type Outlook

• Blood-based sample collection holds 87.4% of sample type share, as peripheral blood draws offer the least invasive collection method with the broadest clinical utility.
• Peripheral blood draws are minimally invasive, well tolerated by patients, and can be easily repeated for serial monitoring applications.
• Urine-based liquid biopsy is becoming a complementary sample type for certain cancer indications where urinary biomarkers offer additional diagnostic information.

Application Outlook

• Cancer diagnosis accounts for 34.0% of application share in 2026.
• Treatment monitoring and recurrence surveillance are increasing applications with growing clinical evidence across oncology care pathways.
• Minimal residual disease monitoring and recurrence surveillance applications are expanding as clinical validation data accumulates.

Cancer Type Outlook

• Lung cancer accounts for 38.0% of cancer type share, supported by the high clinical need for non-invasive molecular profiling in advanced NSCLC treatment selection.
• Liquid biopsy guides therapy selection for EGFR, ALK, and other targetable mutations in lung cancer treatment pathways.
• Breast cancer and colorectal cancer represent additional major application areas for treatment decision making and longitudinal disease monitoring.

Regional Outlook

China

• China leads at 20.0% CAGR through 2036 — the fastest country-level market in the study.
• Government precision medicine investment and hospital molecular diagnostics laboratory expansion are accelerating liquid biopsy adoption.
• Domestic liquid biopsy companies are developing cost-competitive testing platforms for the Chinese healthcare market.

India

• India is projected to register 18.5% CAGR through 2036.
• Private oncology center investment and growing precision medicine awareness are creating access pathways for liquid biopsy adoption.
• Cost-effective test pricing models adapted for the Indian market are making liquid biopsy accessible to a broader patient population.

Germany

• Germany is projected to register 17.0% CAGR through 2036.
• Advanced hospital diagnostics infrastructure and strong clinical research programs support liquid biopsy adoption.
• G-BA health technology assessment decisions influence national coverage for liquid biopsy tests.

Brazil

• Brazil is projected to register 15.5% CAGR through 2036.
• Expanding private oncology infrastructure and growing awareness of precision medicine approaches are creating adoption pathways.
• International diagnostic company partnerships with Brazilian laboratories are enabling access to validated liquid biopsy platforms.

United States

• The United States is projected to register 14.1% CAGR through 2036.
• Established Medicare coverage for key liquid biopsy indications and integration into NCCN clinical guidelines sustain market leadership.
• Commercial reference laboratories provide national distribution infrastructure for liquid biopsy testing with rapid turnaround times.

United Kingdom

• The United Kingdom is projected to register 12.6% CAGR through 2036.
• NHS genomic medicine programs and cancer research infrastructure support structured adoption of liquid biopsy technologies.
• NICE technology appraisal processes are evaluating liquid biopsy tests for cost-effectiveness and NHS-wide deployment.

Competitive Landscape

Overview

• Guardant Health, Illumina, Inc., Bio-Rad Laboratories, Roche Diagnostics, and Natera, Inc. maintain leading positions through validated test platforms and sequencing technology infrastructure.
• Exact Sciences Corporation and Foundation Medicine hold strong positions through focused oncology diagnostic strategies and established payer coverage.
• Companies with validated multi-cancer detection platforms and established laboratory distribution networks are positioned to capture expanding demand.
• Guardant Health leads on commercial liquid biopsy test volume through the Guardant360 platform for comprehensive genomic profiling.
• Roche Diagnostics and Illumina sit across the value chain, providing underlying sequencing and assay platforms for laboratory-developed liquid biopsy tests.

Key Players

Integrated Producers

• Guardant Health
• Roche Diagnostics
• Illumina, Inc.

Specialty Suppliers

• Natera, Inc.
• Exact Sciences Corporation
• Foundation Medicine
• Bio-Rad Laboratories

Regional Players

• Freenome Holdings
• Delfi Diagnostics
• Haystack Oncology
• BillionToOne